Axovant Gene Therapies Ltd

NASDAQ:AXGT   3:59:45 PM EDT
3.81
+0.31 (+8.86%)
Other Pre-Announcement

Axovant Gene Therapies Receives Rare Pediatric Disease Designation For Axo-Aav-Gm1 For Gm1 Gangliosidosis

Published: 10/09/2020 11:06 GMT
Axovant Gene Therapies Ltd. (AXGT) - Axovant Gene Therapies Receives Rare Pediatric Disease Designation for Axo-aav-gm1 for Gm1 Gangliosidosis.
Axovant Gene Therapies - Expects to Initiate High Dose Cohort Which Includes Infantile and Juvenile Patients in Second Half of 2020.
Axovant Gene Therapies - On-track to Report 6-month Stage 1 Data From Low Dose Juvenile Cohort by Q4 of 2020.